Webinar: Managing Complex Patients Not Eligible for Simplified Hepatitis C Treatment

Date: Thursday, October 16, 10:00 am - 11:00 am (EDT)

In collaboration with The American Association for the Study of Liver Diseases (AASLD) Hepatitis C Special Interest Group (HCV SIG) and The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Viral Hepatitis (ESGVH)

Moderators:  Ponni V. Perumalswami, MD (AASLD HCV SIG), İmran Hasanoğlu, MD (ESGVH)
Panelists: David Goldberg, M.D., MSCE. University of Miami. USA, Massimo Puoti, M.D. University of Milano Bicocca. Italy

This international webinar is a collaborative between the American Association for the Study of Liver Diseases (AASLD) and the European Society of Clinical Microbiology and Infectious Diseases (ESMID) Study Group for Viral Hepatitis (ESGVH) and will describe the diagnosis, testing and treatment of Hepatitis C virus (HCV) in complex patients. The moderators and panelists will describe the key clinical challenges in the management of ineligible patients of the simplified HCV treatment, identify evidence-based strategies for managing HCV in patients with liver-related conditions, describe the unique considerations in treating HCV in immunosuppressed patients including those receiving immunosuppressive therapy, and apply practical approaches to HCV treatment in medically complex patients.

This activity is appropriate for hepatologists, gastroenterologists, surgeons, infectious disease specialists, nurse practitioners, pharmacists, physician assistants, fellows/trainees.

By the end of this activity, participants should be able to:
-Identify key clinical challenges in the management of patients not eligible for simplified hepatitis C virus (HCV) treatment.
-Evaluate evidence-based strategies for managing HCV in patients with liver-related conditions.
-Recognize the unique considerations in treating HCV in immunosuppressed patients, including those receiving immunosuppressive therapy.
-Apply practical approaches to HCV treatment in medically complex patients, balancing virologic cure, comorbidity management, and long-term risk reduction.

 This activity will not offer CE Credits.